Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease
about
Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancerPaclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.Chemotherapy for ovarian cancer: current concepts.Role of chemotherapy in the management of ovarian cancer.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri InstRefractory fallopian tube carcinoma - current perspectives in pathogenesis and management.A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.Topotecan: a new topoisomerase I inhibiting antineoplastic agent.Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
P2860
Q33386456-89F2DF88-4F87-4B31-8BF3-191B95A96D7DQ33498535-C8F76A39-2049-4B2C-B541-0C687F786098Q33742794-1E035A93-5035-4255-9733-C932E127D010Q34734126-F0F33A87-5A00-45B3-8A4A-9B9ED3DB0746Q35088311-8FCD017E-4977-4F27-B0CE-F5E2B0C01EA1Q35977532-FA42E399-31A3-4662-903F-D949CFBB469DQ36694220-03EF395D-3D7B-4365-9068-CA8A719E30AEQ37553978-3ED82D27-4A04-446A-B137-2AF94F141C29Q40642695-E457A2F8-61E2-4707-9AFB-DD9B450621E5Q42689189-8BA77CFF-1F53-4F9B-94DE-7EDA7CB0539EQ43824337-AEEF0BD2-8889-4555-A5C7-ED626C681E59Q46934871-44D0A1EA-D13E-4A2B-8099-118B8EF90581Q55493644-4215C043-F529-49A4-A766-C4C779A284EC
P2860
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease
description
1992 nî lūn-bûn
@nan
1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@ast
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@en
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@nl
type
label
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@ast
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@en
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@nl
prefLabel
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@ast
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@en
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@nl
P2093
P1476
Ifosfamide and mesna in previo ...... in platinum-resistant disease
@en
P2093
B Reichman
L Almadrones
P356
10.1200/JCO.1992.10.2.243
P407
P577
1992-02-01T00:00:00Z